Alnylam Pharmaceuticals

ALNYNASDAQ

RNA interference therapeutics platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

rare disease cardiometabolic genetic medicine

Key figures from SEC filings

ALNY filings on EDGAR →

Cash & investments

$3.31B

at June 30, 2026 (10-Q)

Quarterly operating burn

No burn

operating cash flow positive, Jan–Jun 2026

Cash runway

—

not a runway: funded by operations

Shares outstanding

133.8M

cover page of the latest filing

Read from ALNY's XBRL financial data; latest filing July 30, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.

Upcoming catalysts

TRITON-PN: Nucresiran in Hereditary ATTR amyloidosis with polyneuropathy — primary completion

2027-12-27

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

TRITON-CM: Nucresiran in ATTR amyloidosis with cardiomyopathy — primary completion

2030-05-28

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

ZENITH: Zilebesiran in Hypertension with high cardiovascular risk — primary completion

2030-09-30

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

Drug	Indication	Phase	Expected data
Amvuttra	ATTR amyloidosis	Approved	Not disclosed	▼
Leqvio (inclisiran), partnered	hypercholesterolemia	Approved	Not disclosed	▼
Zilebesiran	hypertension	Phase 3	Not disclosed	▼

Analysis

We have not yet written an analysis of Alnylam Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.

Trade ALNY commission-free on Webullvia Webull · Affiliate

Comparable companies

Ionis PharmaceuticalsArrowhead PharmaceuticalsSarepta Therapeutics

Sponsor's late-stage trial record

Alnylam Pharmaceuticals has 45 Phase 2 or 3 studies on ClinicalTrials.gov: 26 completed, 6 stopped early, 13 ongoing.

Completed

Stopped early

Ongoing

Stopped early

NCT05761301Phase 1/2 · started 2023 · terminated
ALN-KHK in type 2 diabetes mellitus (t2dm) · n=49
Reason given: Business reasons (not safety related)
NCT05256810Phase 1/2 · started 2022 · terminated
ALN-XDH in gout · n=44
Reason given: The Sponsor elected not to continue with the study
NCT05161936Phase 2 · started 2022 · terminated
Lumasiran in recurrent calcium oxalate kidney stone disease · n=2
Reason given: Study terminated early due to low enrollment
NCT03841448Phase 2 · started 2019 · terminated
Placebo in iga nephropathy (igan) · n=31
Reason given: Study was terminated early having identified clinically meaningful magnitude of proteinuria reduction due to cemdisiran (study goal). Participants completed DBT period\&were in OLE period. Sponsor had no concerns with safety\&integrity of participants.
NCT03767829Phase 1/2 · started 2018 · terminated
ALN-AAT02 in zz type alpha-1 antitrypsin deficiency liver disease · n=32
Reason given: The sponsor decided not to proceed with Part B for business reasons.
NCT03303313Phase 2 · started 2017 · withdrawn
Cemdisiran in atypical hemolytic uremic syndrome · n=0
Reason given: Study terminated early due to lack of enrollment.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.